ATE533777T1 - Hiv-vif-mutanten - Google Patents

Hiv-vif-mutanten

Info

Publication number
ATE533777T1
ATE533777T1 AT06765488T AT06765488T ATE533777T1 AT E533777 T1 ATE533777 T1 AT E533777T1 AT 06765488 T AT06765488 T AT 06765488T AT 06765488 T AT06765488 T AT 06765488T AT E533777 T1 ATE533777 T1 AT E533777T1
Authority
AT
Austria
Prior art keywords
amino acid
sequence
vif
hiv vif
representing
Prior art date
Application number
AT06765488T
Other languages
English (en)
Inventor
Chiara Bovolenta
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0504770A external-priority patent/GB0504770D0/en
Priority claimed from GB0510888A external-priority patent/GB0510888D0/en
Application filed by Molmed Spa filed Critical Molmed Spa
Application granted granted Critical
Publication of ATE533777T1 publication Critical patent/ATE533777T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06765488T 2005-03-08 2006-03-07 Hiv-vif-mutanten ATE533777T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0504770A GB0504770D0 (en) 2005-03-08 2005-03-08 HIV Vif
GB0510888A GB0510888D0 (en) 2005-05-26 2005-05-26 Hiv vif
PCT/IB2006/001519 WO2006111866A2 (en) 2005-03-08 2006-03-07 Hiv vif mutants

Publications (1)

Publication Number Publication Date
ATE533777T1 true ATE533777T1 (de) 2011-12-15

Family

ID=37115522

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06765488T ATE533777T1 (de) 2005-03-08 2006-03-07 Hiv-vif-mutanten

Country Status (9)

Country Link
US (1) US8912152B2 (de)
EP (1) EP1883649B1 (de)
JP (1) JP5324912B2 (de)
KR (1) KR101411272B1 (de)
AT (1) ATE533777T1 (de)
AU (1) AU2006238617B2 (de)
CA (1) CA2599525C (de)
ES (1) ES2377829T3 (de)
WO (1) WO2006111866A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164659A1 (en) 2009-08-05 2012-06-28 Nexigen Gmbh Human hcv-interacting proteins and methods of use
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
KR102458904B1 (ko) * 2020-06-19 2022-11-01 숙명여자대학교산학협력단 신규의 bmpr2 유전자 기능획득 돌연변이체 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198784B2 (en) * 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
EP1629003B1 (de) * 2003-05-23 2008-03-12 Oregon Health & Science University Verfahren zur identifikation von inhibitoren

Also Published As

Publication number Publication date
JP5324912B2 (ja) 2013-10-23
AU2006238617A1 (en) 2006-10-26
KR101411272B1 (ko) 2014-07-03
JP2008532510A (ja) 2008-08-21
EP1883649A2 (de) 2008-02-06
CA2599525A1 (en) 2006-10-26
US20080286248A1 (en) 2008-11-20
US8912152B2 (en) 2014-12-16
AU2006238617B2 (en) 2012-08-02
EP1883649B1 (de) 2011-11-16
WO2006111866A3 (en) 2007-04-12
CA2599525C (en) 2015-05-26
KR20070118624A (ko) 2007-12-17
WO2006111866A2 (en) 2006-10-26
ES2377829T3 (es) 2012-04-02

Similar Documents

Publication Publication Date Title
MX2007009489A (es) Microorganismos que comprenden enzimas expresadas con baja actividad de eliminacion gamma.
TNSN07142A1 (en) Enzymes
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
ATE509951T1 (de) Humanes interferon-beta-mutein
EA201300455A1 (ru) Полипептиды с пермеазной активностью
DK2333097T3 (da) Enzymer med alpha-amylase-aktivitet og fremgangsmåder til anvendelse deraf
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
MX2020011083A (es) Proteina.
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
ATE533777T1 (de) Hiv-vif-mutanten
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
ATE523360T1 (de) Gelenk- und/oder lagereinheit
ES2562919T3 (es) Proteína y secuencia de ADN que codifica una actividad del tipo de la subtilisina adaptada al frío
NO20010785D0 (no) Tablett som kan deles eksakt
SI1945657T1 (sl) Muteini glikozilacijskih mest tlr in postopki uporabe
EP1899460A4 (de) Herstellung von rekombinanten selenoprotein-mutanten mit verbesserter katalytischer aktivität
WO2008128526A3 (de) Verwendung von egfl7 zur modulation von stammzellen
WO2005057486A3 (en) Protein engineering with analogous contact environments
TH77040S (th) อิฐบล็อค
TH22270S1 (th) อิฐบล็อค
TH78102S (th) อิฐบล็อก
TH22300S1 (th) อิฐบล็อก
TH80114S (th) อิฐบล็อก